Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CENCORA, INC. via CENCORA, INC.
2017 · second_quarter · Q2
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Source: Senate LDA
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017.
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Women Veterans and Families Health Services Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Women Veterans and Families Health Services Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Medication Therapy Management Empowerment Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Medication Therapy Management Empowerment Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Medication Therapy Management Empowerment Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
Medication Therapy Management Empowerment Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
Pharmacy and Medically Underserved Areas Enhancement Act
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
A bill to amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare, and for other purposes.
Client: CENCORA, INC. · Firm: CENCORA, INC.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Implementation of the Veterinarian Food Directive; Antimicrobial Resistance.
Repeal of LIFO (last in, first out).
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. via CENCORA, INC.
2017 · first_quarter · Q1
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017.
Repeal of LIFO (last in, first out).
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
Implementation of the Veterinarian Food Directive; Antimicrobial Resistance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. via CENCORA, INC.
2016 · fourth_quarter · Q4
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Repeal of LIFO (last in, first out).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. via CENCORA, INC.
2016 · third_quarter · Q3
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
Repeal of LIFO (last in, first out).
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. via CENCORA, INC.
2016 · second_quarter · Q2
Repeal of LIFO (last in, first out).
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. via CENCORA, INC.
2016 · first_quarter · Q1
Repeal of LIFO (last in, first out).
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
CENCORA, INC. via CENCORA, INC.
2015 · fourth_quarter · Q4
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Repeal of LIFO (last in, first out).
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
CENCORA, INC. via CENCORA, INC.
2015 · third_quarter · Q3
Repeal of LIFO (last in, first out).
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE